223 related articles for article (PubMed ID: 16718271)
41. Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha: A controlled, randomised multicentre trial.
Stadler R; Luger T; Bieber T; Köhler U; Linse R; Technau K; Schubert R; Schroth K; Vakilzadeh F; Volkenandt M; Gollnick H; Von Eick H; Thoren F; Strannegård O
Acta Oncol; 2006; 45(4):389-99. PubMed ID: 16760174
[TBL] [Abstract][Full Text] [Related]
42. Carboplatin and vinorelbine combined with subcutaneous interleukin-2 in metastatic melanoma with poor prognosis.
Vuoristo MS; Vihinen P; Skyttä T; Tyynelä K; Kellokumpu-Lehtinen P
Anticancer Res; 2009 May; 29(5):1755-9. PubMed ID: 19443399
[TBL] [Abstract][Full Text] [Related]
43. Combined liver and pancreas resection with biochemotherapy for metastatic ocular melanoma.
Camp R; Lind DS; Hemming AW
J Hepatobiliary Pancreat Surg; 2002; 9(4):519-21. PubMed ID: 12483277
[TBL] [Abstract][Full Text] [Related]
44. Bleomycin, vinorelbine and trofosfamide in relapsed stage IV cutaneous malignant melanoma patients.
Atzpodien J; Morawek L; Fluck M; Reitz M
Cancer Chemother Pharmacol; 2009 Oct; 64(5):901-5. PubMed ID: 19229537
[TBL] [Abstract][Full Text] [Related]
45. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.
Bedikian AY; Millward M; Pehamberger H; Conry R; Gore M; Trefzer U; Pavlick AC; DeConti R; Hersh EM; Hersey P; Kirkwood JM; Haluska FG;
J Clin Oncol; 2006 Oct; 24(29):4738-45. PubMed ID: 16966688
[TBL] [Abstract][Full Text] [Related]
46. Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma.
Piperno-Neumann S; Diallo A; Etienne-Grimaldi MC; Bidard FC; Rodrigues M; Plancher C; Mariani P; Cassoux N; Decaudin D; Asselain B; Servois V
Oncologist; 2016 Mar; 21(3):281-2. PubMed ID: 26911405
[TBL] [Abstract][Full Text] [Related]
47. Metastatic uveal melanoma: is there a role for conventional chemotherapy? - A single center study based on 58 patients.
Pons F; Plana M; Caminal JM; Pera J; Fernandes I; Perez J; Garcia-Del-Muro X; Marcoval J; Penin R; Fabra A; Piulats JM
Melanoma Res; 2011 Jun; 21(3):217-22. PubMed ID: 21467954
[TBL] [Abstract][Full Text] [Related]
48. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
[TBL] [Abstract][Full Text] [Related]
49. Lack of benefit of adjunctive chemotherapy in stage I malignant melanoma: a Southwest Oncology Group Study.
Tranum BL; Dixon D; Quagliana J; Neidhart J; Balcerzak SP; Costanzi JH; Fabian CJ; Neilan B; Maloney T; O'Bryan RM
Cancer Treat Rep; 1987 Jun; 71(6):643-4. PubMed ID: 3581104
[TBL] [Abstract][Full Text] [Related]
50. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years?
Eggermont AM; Kirkwood JM
Eur J Cancer; 2004 Aug; 40(12):1825-36. PubMed ID: 15288283
[TBL] [Abstract][Full Text] [Related]
51. Treatment of metastatic uveal melanoma with intravenous fotemustine.
Spagnolo F; Grosso M; Picasso V; Tornari E; Pesce M; Queirolo P
Melanoma Res; 2013 Jun; 23(3):196-8. PubMed ID: 23624366
[TBL] [Abstract][Full Text] [Related]
52. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma.
Del Prete SA; Maurer LH; O'Donnell J; Forcier RJ; LeMarbre P
Cancer Treat Rep; 1984 Nov; 68(11):1403-5. PubMed ID: 6541973
[No Abstract] [Full Text] [Related]
53. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
54. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
55. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
Tarhini AA; Millward M; Mainwaring P; Kefford R; Logan T; Pavlick A; Kathman SJ; Laubscher KH; Dar MM; Kirkwood JM
Cancer; 2009 Feb; 115(4):859-68. PubMed ID: 19140204
[TBL] [Abstract][Full Text] [Related]
56. Phase II multicenter trial of anthracycline rechallenge with pegylated liposomal doxorubicin plus cyclophosphamide for first-line therapy of metastatic breast cancer previously treated with adjuvant anthracyclines.
Trudeau ME; Clemons MJ; Provencher L; Panasci L; Yelle L; Rayson D; Latreille J; Vandenberg T; Goel R; Zibdawi L; Rahim Y; Pouliot JF
J Clin Oncol; 2009 Dec; 27(35):5906-10. PubMed ID: 19858391
[TBL] [Abstract][Full Text] [Related]
57. Complex combination biochemotherapy regimen in advanced metastatic melanoma in a non-intensive care unit: toxicity or benefit?
Hofmann MA; Sterry W; Trefzer U
Jpn J Clin Oncol; 2007 Mar; 37(3):224-9. PubMed ID: 17472972
[TBL] [Abstract][Full Text] [Related]
58. Prognostic factors that determine the long-term survival of patients with unresectable metastatic melanoma.
Bedikian AY; Johnson MM; Warneke CL; Papadopoulos NE; Kim K; Hwu WJ; McIntyre S; Hwu P
Cancer Invest; 2008 Jul; 26(6):624-33. PubMed ID: 18584354
[TBL] [Abstract][Full Text] [Related]
59. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
60. Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicentre trial.
Neuber K; Reinhold U; Deutschmann A; Pföhler C; Mohr P; Pichlmeier U; Baumgart J; Hauschild A
Melanoma Res; 2003 Feb; 13(1):81-5. PubMed ID: 12569289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]